Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Assets (2016 - 2025)

Altimmune (ALT) has disclosed Assets for 16 consecutive years, with $218.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 47.74% to $218.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $218.4 million, a 47.74% increase, with the full-year FY2024 number at $139.3 million, down 33.87% from a year prior.
  • Assets was $218.4 million for Q3 2025 at Altimmune, up from $190.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $264.3 million in Q1 2021 to a low of $139.3 million in Q4 2024.
  • A 5-year average of $199.3 million and a median of $205.7 million in 2022 define the central range for Assets.
  • Peak YoY movement for Assets: skyrocketed 387.25% in 2021, then tumbled 33.87% in 2024.
  • Altimmune's Assets stood at $218.9 million in 2021, then fell by 5.45% to $206.9 million in 2022, then increased by 1.79% to $210.6 million in 2023, then crashed by 33.87% to $139.3 million in 2024, then surged by 56.81% to $218.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Assets are $218.4 million (Q3 2025), $190.4 million (Q2 2025), and $157.3 million (Q1 2025).